TITLE:
Study Evaluating ReFacto in Hemophilia A Undergoing Major Surgery

CONDITION:
Hemophilia A

INTERVENTION:
ReFacto

SUMMARY:

      The primary objective of this clinical research study is to evaluate the safety and efficacy
      of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the
      chromogenic substrate assay at the local laboratory.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 6 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Age  6 years

          -  Male previously treated patients (150 Exposure Days) with moderate or severe
             hemophilia A (i.e.  5% FVIII:C) who will undergo elective major surgery that is
             anticipated to require at least 6 consecutive days of daily factor VIII (FVIII)
             infusions (surgical and post-surgical prophylaxis)

          -  Ability to adhere to the protocol requirements

        Exclusion Criteria:

          -  Hypersensitivity to ReFacto, murine allergen, or hamster allergen 2 History of FVIII
             inhibitor or current inhibitor, defined as > 0.6 BU

          -  Prior participation in this study

          -  Any concomitant bleeding disorder other than hemophilia A
      
